GLP-1 reduces metalloproteinase-14 and soluble endoglin induced by both hyperglycemia and hypoglycemia in type 1 diabetes

Endocrine

Volumn 50, Issue 2, 2015, Pages 508-511

  Ceriello, Antonio ^a,b   La Sala, Lucia ^a   De Nigris, Valeria ^a   Pujadas, Gemma ^a   Testa, Roberto ^c   Uccellatore, Annachiara ^d,e   Genovese, Stefano ^d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INRCA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; GLUCAGON LIKE PEPTIDE 1; MATRIX METALLOPROTEINASE 14; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; ADULT; METABOLISM; YOUNG ADULT;

ADULT; ANTIGENS, CD; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MATRIX METALLOPROTEINASE 14; RECEPTORS, CELL SURFACE; YOUNG ADULT;

EID: 84945447312     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0565-2     Document Type: Letter

References (17)

1. C. Bernabeu, B.A. Conley, C.P. Vary, Novel biochemical pathways of endoglin in vascular cell physiology. J. Cell. Biochem. 102, 1375–1388 (2007)
2. Y.S. Jang, I.H. Choi, Contrasting roles of different endoglin forms in atherosclerosis. Immune Netw. 14, 237–240 (2014)
3. A.M. Blázquez-Medela, L. García-Ortiz, M.A. Gómez-Marcos, J.I. Recio-Rodríguez, A. Sánchez-Rodríguez, J.M. López-Novoa, C. Martínez-Salgado, Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 8, 86 (2010)
4. T. Ikemoto, Y. Hojo, H. Kondo, N. Takahashi, M. Hirose, Y. Nishimura, T. Katsuki, K. Shimada, K. Kario, Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels 27, 344–351 (2012)
5. S. Uemura, H. Matsushita, W. Li, A.J. Glassford, T. Asagami, K.H. Lee, D.G. Harrison, P.S. Tsao, Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ. Res. 88, 1291–1298 (2001)
6. L. La Sala, G. Pujadas, V. De Nigris, S. Canivell, A. Novials, S. Genovese, A. Ceriello, Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. Acta Diabetol. (2014). doi:10.1007/s00592-014-0670-3
7. S. Tölle, GLP-1 analogues in treatment of type 1 diabetes mellitus. Dtsch. Med. Wochenschr. 139, 2123–2126 (2014)
8. A. Ceriello, A. Novials, E. Ortega, S. Canivell, L. La Sala, G. Pujadas, K. Esposito, D. Giugliano, S. Genovese, Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36, 2346–2350 (2013)
9. H. Oeseburg, R.A. de Boer, H. Buikema, P. van der Harst, W.H. van Gilst, H.H. Silljé, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler. Thromb. Vasc. Biol. 30, 1407–1414 (2010)
10. M. Balteau, A. Van Steenbergen, A.D. Timmermans, C. Dessy, G. Behets-Wydemans, N. Tajeddine, D. Castanares-Zapatero, P. Gilon, J.L. Vanoverschelde, S. Horman, L. Hue, L. Bertrand, C. Beauloye, AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 307, H1120–H1133 (2014)
11. R.A. Kowluru, M. Kanwar, Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Radic. Biol. Med. 46, 1677–1685 (2009)
12. S. Verma, K. Kesh, N. Ganguly, S. Jana, S. Swarnakar, Matrix metalloproteinases and gastrointestinal cancers: impacts of dietary antioxidants. World J. Biol. Chem. 5, 355–376 (2014)
13. A. Ceriello, Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur. J. Cardiovasc. Prev. Rehabil. 17(Suppl 1), S15–S19 (2010)
14. G. Gruden, F. Barutta, N. Chaturvedi, C. Schalkwijk, C.D. Stehouwer, D.R. Witte, J.H. Fuller, P.C. Perin, G. Bruno, Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 35, 1598–1604 (2012)
15. J.L. Johnson, N.P. Jenkins, W.C. Huang, K. Di Gregoli, G.B. Sala-Newby, V.P. Scholtes, F.L. Moll, G. Pasterkamp, A.C. Newby: Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediators Inflamm. 2014, 276457 (2014). doi:10.1155/2014/276457
16. K. Okada, K. Kotani, H. Yagyu, A. Ando, J. Osuga, S. Ishibashi, Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine 47, 962–964 (2014)
17. G. Chang, D. Zhang, H. Yu, P. Zhang, Y. Wang, A. Zheng, S. Qin, Cardioprotective effects of exenatide against oxidative stress-induced injury. Int. J. Mol. Med. 32, 1011–1020 (2013)